Spontaneous regression of advanced hepatocellular carcinoma: A case report

Cases Journal

Volumn 2, Issue 8, 2009, Pages

  Hsu, Chuan Yuan ^a   Sun, Po Lin ^a   Chang, Hong Cheng ^a   Perng, Daw Shyong ^a   Chen, Yaw Sen ^a  

^a I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS C ANTIBODY; SILYMARIN; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CASE REPORT; CHEMOEMBOLIZATION; HEPATITIS C; HEPATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PORTAL VEIN THROMBOSIS; RADIOFREQUENCY ABLATION; TUMOR BIOPSY;

EID: 77953367715     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-6251     Document Type: Article

References (14)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
2. Everson TC, Cole WH: Spontaneous regression of cancer. Philadelphia: WB Saunders; 1966.
3. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
4. Cole WH: Efforts to explain spontaneous regression of cancer. J Surg Oncol 1981, 17:201-209.
5. Adam CR, Erin MT, Nooman G: Spontaneous regression of hepatocellular carcinoma is possible and might have implications for future therapies. Eur J Gastroenterol Hepatol 2008, 20:804-809.
6. Higuchi T, Kikuchi M, Okazaki M: Hepatocellular carcinoma after transcatheter hepatic arterial embolization: a histopathologic study of 84 resected cases. Cancer 1994, 73:2259-2267.
7. Grossmann M, Hoermann R, Weiss M, Jauch KW, Oertel H, Staebler A, Mann K, Engelhardt D: Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol 1995, 90:1500-1503.
8. Yanaida Y, Kohno H, Yoshida K, Hirose Y, Yamada Y, Mori H, Tanaka T: Dietary silymarin suppresses 4-nitroquinoline 1-oxide induced tongue carcinogenesis in male F344 rats. Carcinogenesis 2002, 23:787-794.
9. Pradeep KI, Mohan CVR, Gobianand K, Karthikeyan S: Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol 2007, 560:110-116.
10. Lah JJ, Cui W, Hu KQ: Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007, 13:5299-5305.
11. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, Jahanshiri Z, Nooridaloii MR: Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 2008, 591:13-20.
12. Ramakrishnan G, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T: Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEAinduced rat hepatocellular carcinoma. Mol Cell Biochem 2008, 313:53-61.
13. Dvořák Z, Vrzal R, Ulrichovám J: Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: a study in human keratinocytes and human hepatoma cells. Cell Biol Toxicol 2006, 22:81-90.
14. Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T: Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif 2009, 42:229-240.